DNDi and BenevolentAI initiated a joint research collaboration in 2022 to deliver a list of potential biological targets (proteins that can be targeted by a potential drug) and drug repurposing candidates that could be effective in preventing progression to severe dengue.

Project updates


The collaboration uses BenevolentAI’s AI tools and biomedical knowledge graph, which is built from diverse and independent data sources, such as scientific literature, patents, genetics, chemistry, clinical trial data, and more. Scientists from DNDi and BenevolentAI began using this artificial intelligence-driven approach to interrogate the underlying mechanisms involved in dengue and rapidly identify therapies that could be repurposed to prevent progression to severe dengue.

The most promising drug candidates identified in the joint research will later be tested in preclinical models and potentially in clinical trials conducted in collaboration with dengue-endemic country partners.